6-碘-2-萘甲酸 | 5042-99-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 6-碘-2-萘甲酸
• 英文名称: 6-Iod-2-naphthoesaeure
• 英文别名: 2-Naphthalenecarboxylic acid, 6-iodo-；6-iodonaphthalene-2-carboxylic acid
• CAS: 5042-99-9
• 化学式: C₁₁H₇IO₂
• 分子量: 298.08
• InChiKey: WVEYKBNTOLJDMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-碘-2-萘甲酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 6-Iodonaphthalene-2-carbonyl chloride
  参考文献：
  名称：

  一系列有力和选择性的线性速激肽NK2受体拮抗剂对C和N末端部分的调节

  摘要：

  本文中，我们描述了一系列新的有效速激肽NK的合成2通过ibodutant的C-和N-末端部分的调制（MEN 15596，受体拮抗剂1）。N末端的苯并[ b ]噻吩环被不同的取代萘和苯并呋喃取代，同时在C末端的四氢吡喃部分评估了进一步的修饰。大多数化合物表现出对人NK 2受体的高亲和力和体外拮抗剂的高效力，表明可以在分子的两个末端引入广泛的取代基，而不会影响与NK 2受体的相互作用。对选定的化合物进行了体内测试，证实了其作为NK的活性2个拮抗剂。特别是，对豚鼠静脉内和静脉内给药后，化合物61b能够拮抗NK 2诱导的结肠收缩，其作用力和作用持续时间与参考化合物1（MEN 15596，ibodutant）完全相同。

  DOI：

  10.1002/cmdc.200900389
• 作为产物：
  描述：

  6-nitro-[2]naphthonitrile 在 镍 氢气 作用下， 以 乙醇 为溶剂， 生成 6-碘-2-萘甲酸
  参考文献：
  名称：

  Adcock,W.; Wells,P.R., Australian Journal of Chemistry, 1965, vol. 18, p. 1351 - 1364

  摘要：

  DOI：

文献信息

• PROCESS FOR PREPARATION OF 6-[3-(1-ADMANTYL)-4-METHOXYPHENYL]-2-NAPHTOIC ACID.
  申请人：Kalvinsh Ivars

  公开号：US20100160677A1

  公开（公告）日：2010-06-24

  A process for preparation of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid from 2-(1-adamantyl)-4-bromanisolee is disclosed, based on transformation of 2-(1-adamantyl)-4-bromanisole into a Grignard's reagent by using metallic magnesium, anhydrous lithium chloride and dibromoethane followed by transmetallation with borates to 3-(adamantyl)-4-methoxyphenylboronic acid, which is converted into 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid esters by Suzuki-Miyaura cross-coupling reaction with alkyl-6-halonaftoates catalyzed by Pd [0] or Pd/phosphine ligands and followed by basic hydrolysis in ethylene glycol or 1,2-propanediol of ester thus obtained into 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid.

  揭示了一种从2-(1-金刚烷基)-4-溴苯甲醚制备6-[3-(1-金刚烷基)-4-甲氧基苯基]-2-萘甲酸的方法，基于将2-(1-金刚烷基)-4-溴苯甲醚转化为格氏试剂，使用金属镁、无水氯化锂和二溴乙烷进行转化，随后通过与硼酸盐的转金属化反应得到3-(金刚烷基)-4-甲氧基苯基硼酸，再通过Suzuki-Miyaura交叉偶联反应与Pd [0]或Pd/膦配体催化的烷基-6-卤代萘酸酯反应，最后在乙二醇或1,2-丙二醇中进行酯的碱性水解，得到6-[3-(1-金刚烷基)-4-甲氧基苯基]-2-萘甲酸。
• [EN] LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF<br/>[FR] COMPOSES DE BASE LINEAIRES POSSEDANT UNE ACTIVITE ANTAGONISTE NK-2 ET FORMULATIONS DE CES COMPOSES
  申请人：MENARINI RICERCHE SPA

  公开号：WO2003037916A2

  公开（公告）日：2003-05-08

  Described herein are compounds of formula (I) useful as antagonists of tachykinins in general, and in particular of neurokinin A; and the pharmaceutical formulations comprising the compounds of formula (I).

  本文描述了一些化合物，其化学式为(I)，可作为缓激肽拮抗剂，特别是神经激肽A的拮抗剂，并且包括化合物(I)的制药配方。
• Linear basic compounds having nk-2 antagonist activity and formulations thereof
  申请人：——

  公开号：US20040259930A1

  公开（公告）日：2004-12-23

  Described herein are compounds of formula (I) useful as antagonists of tachykinins in general, and in particular of neurokinin A; and the pharmaceutical formulations comprising the compounds of formula (I) 1

  本文描述了式（I）化合物，可作为缓激肽拮抗剂，特别是神经激肽A的拮抗剂，并且包括含有式（I）化合物的药物制剂。
• Albicidin derivatives, their use and synthesis
  申请人：TECHNISCHE UNIVERSITAET BERLIN

  公开号：US10308595B2

  公开（公告）日：2019-06-04

  Antibiotically active compounds characterized by general formula (I), wherein X1, BB, BC, BD, BE and X2 are building blocks with D1, D2, D3, D4 or D5 being linkers which include carbon, sulphur, nitrogen, phosphor and/or oxygen atoms and which are covalently connecting the moities BA and BB, BB and BC, BC and BD, BD and BE and BE and BF, respectively, and wherein in particular the building block BC comprises an amino acid derivative. The compounds for use in a method of treatment of diseases, in particular for use in a method of treatment of bacterial infections are also disclosed.

  抗生素活性化合物，其特征为通式(I)，其中X1、BB、BC、BD、BE和X2为结构单元，D1、D2、D3、D4或D5为连接体，包括碳原子、硫原子、氮原子、磷原子和/或氧原子，并分别以共价方式连接摩尔体BA和BB、BB和BC、BC和BD、BD和BE以及BE和BF，其中特别是结构单元BC包括氨基酸衍生物。还公开了用于疾病治疗方法，特别是用于细菌感染治疗方法的化合物。
• Piperazine-2,3-dicarboxylic Acid Derivatives as Dual Antagonists of NMDA and GluK1-Containing Kainate Receptors
  作者：Mark W. Irvine、Blaise M. Costa、Daniel Dlaboga、Georgia R. Culley、Richard Hulse、Caroline L. Scholefield、Palmi Atlason、Guangyu Fang、Richard Eaves、Richard Morley、Maria B. Mayo-Martin、Mascia Amici、Zuner A. Bortolotto、Lucy Donaldson、Graham L. Collingridge、Elek Molnár、Daniel T. Monaghan、David E. Jane

  DOI：10.1021/jm201230z

  日期：2012.1.12

  Competitive N-methyl-D-aspartate receptor (NMDAR) antagonists bind to the GluN2 subunit, of which there are four types (GluN2A-D). We report that some N-1-substituted derivatives of cis-piperazine-2,3-dicarboxylic acid display improved relative affinity for GluN2C and GluN2D versus GluN2A and GluN2B. These derivatives also display subtype selectivity among the more distantly related kainate receptor family. Compounds 18i and (-)-4 were the most potent kainate receptor antagonists, and 18i was selective for GluK1 versus GluK2, GluK3 and AMPA receptors. Modeling studies revealed structural features required for activity at GluK1 subunits and suggested that S674 was vital for antagonist activity. Consistent with this hypothesis, replacing the equivalent residue in GluK3 (alanine) with a serine imparts 18i antagonist activity. Antagonists with dual GluN2D and GluK1 antagonist activity may have beneficial effects in various neurological disorders. Consistent with this idea, antagonist 18i (30 mg/kg ip) showed antinociceptive effects in an animal model of mild nerve injury.